Market Cap
Amgen Inc.
$166.77 Billion
USD as of July 1, 2024
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
AbbVie | $295.34 B |
AstraZeneca | $236.45 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Amgen Inc. is a multinational biotechnology and pharmaceutical company. It produces various drugs, including Neulasta, which prevents infections for patients undergoing cancer chemotherapy, Enbrel, a necrosis blocker for the treatment of autoimmune diseases. Focusing on molecular biology and biochemistry, Amgen aims at developing health care through recombinant DNA technology.
Amgen Inc. has the following listings and related stock indices.
Stock: NASDAQ: AMGN
Stock: FSX: AMG
Stock: OTC: AMVMF
Stock: XETR: AMG
The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.